HCW Biologics (HCWB) Income from Continuing Operations (2020 - 2025)
HCW Biologics' (HCWB) quarterly Income from Continuing Operations came in at 4673950.0 in Q4 2025, down 40.64% YoY from 7873856.08 in Q4 2024, and down 36.7% on a QoQ basis from 3419196.0 in Q3 2025.
HCW Biologics (HCWB) Income from Continuing Operations (2020 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 6 years of Income from Continuing Operations data on file, last reported at 4673950.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 40.64% year-over-year to 4673950.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 14007561.0 (up 53.35% YoY) and the FY2025 annual result came in at 40588186.0, up 27.11% from the prior year.
- Income from Continuing Operations eased to 4673950.0 in Q4 2025, from 3419196.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1894739.0 in Q1 2022 to a low of 15295676.0 in Q2 2024.
- A 5-year average of 5176813.6 and a median of 4159570.5 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 309.53% — and 2025, when it surged 75.86%.
- Tracing HCWB's Income from Continuing Operations over 5 years: stood at 4236719.0 in 2021, then slumped by 35.99% to 5761713.0 in 2022, then sank by 86.87% to 10766768.0 in 2023, then jumped by 69.13% to 3323352.0 in 2024, then sank by 40.64% to 4673950.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4673950.0 (Q4 2025), 3419196.0 (Q3 2025), and 3692791.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | -5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.67 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -3.69 Mn |
| Mar 31, 2025 | -2.22 Mn |
| Dec 31, 2024 | -3.32 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -15.30 Mn |
| Mar 31, 2024 | -7.49 Mn |
| Dec 31, 2023 | -10.77 Mn |
| Sep 30, 2023 | -6.88 Mn |
| Jun 30, 2023 | -6.31 Mn |
| Mar 31, 2023 | -5.45 Mn |
| Dec 31, 2022 | -5.76 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -3.68 Mn |
| Mar 31, 2022 | -1.89 Mn |
| Dec 31, 2021 | -4.24 Mn |
| Sep 30, 2021 | -4.13 Mn |
| Jun 30, 2021 | -2.79 Mn |
| Mar 31, 2021 | -3.41 Mn |